NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS

被引：0
|
作者：
Dougados, M. [1 ]
Kiltz, U. [2 ,3 ]
Kivitz, A. [4 ]
Pavelka, K. [5 ]
Rohrer, S. [5 ]
Mccreddin, S. [7 ]
Quebe-Fehling, E. [6 ]
Porter, B. [8 ]
Talloczy, Z. [8 ]
机构：
[1] Univ Paris, Dept Rheumatol, Hop Cochin, Paris, France
[2] Rheumazentrum Ruhrgebiet, Herne, Germany
[3] Ruhr Univ, Bochum, Germany
[4] Altoona Ctr Clin Res, Duncansville, PA USA
[5] Inst Rheumatol, Dept Rheumatol, Prague, Czech Republic
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Ireland Ltd, Dublin, Ireland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.824
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0374
引用
收藏
页码：415 / 416
页数：2
相关论文
共 50 条
  • [1] Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials
    Dougados, Maxime
    Kiltz, Uta
    Kivitz, Alan
    Pavelka, Karel
    Rohrer, Susanne
    McCreddin, Suzanne
    Quebe-Fehling, Erhard
    Porter, Brian
    Talloczy, Zsolt
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (02) : 205 - 213
  • [2] Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials
    Maxime Dougados
    Uta Kiltz
    Alan Kivitz
    Karel Pavelka
    Susanne Rohrer
    Suzanne McCreddin
    Erhard Quebe-Fehling
    Brian Porter
    Zsolt Talloczy
    Rheumatology International, 2022, 42 : 205 - 213
  • [3] Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
    Kiltz, Uta
    Baraliakos, Xenofon
    Brandt-Jrgens, Jan
    Wagner, Ulf
    Lieb, Sebastian
    Sieder, Christian
    Mann, Christian
    Braun, Juergen
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1886 - 1888
  • [4] EVALUATION OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE MULTICENTER, RANDOMISED, DOUBLE-BLIND, PHASE IV ASTRUM-TRIAL
    Kiltz, U.
    Baraliakos, X.
    Brandt-Juergens, J.
    Wagner, U.
    Lieb, S.
    Sieder, C.
    Mann, C.
    Braun, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 714 - 715
  • [5] EVALUATION OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: MULTICENTER, RANDOMISED, DOUBLE-BLIND, PHASE IV ASTRUM-TRIAL
    Kiltz, U.
    Baraliakos, X.
    Brandt-Juergens, J.
    Wagner, U.
    Lieb, S.
    Sieder, C.
    Mann, C.
    Braun, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1225 - 1226
  • [6] Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
    Braun, Juergen
    Baraliakos, Xenofon
    Deodhar, Atul
    Poddubnyy, Denis
    Emery, Paul
    Delicha, Eumorphia M.
    Talloczy, Zsolt
    Porter, Brian
    RHEUMATOLOGY, 2019, 58 (05) : 859 - 868
  • [7] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE 3 TRIAL, MEASURE 2
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Richardo
    Cohen, Martin
    Delicha, Eumorphia-Maria
    Rohrer, Susanne
    Richards, Hanno
    RHEUMATOLOGY, 2019, 58
  • [8] 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan J.
    Blanco, Ricardo
    Cohen, Martin
    Pavelka, Karel
    Delicha, Eumorphia M.
    Stefanska, Anna
    Richards, Hanno B.
    Rohrer, Susanne
    LANCET RHEUMATOLOGY, 2020, 2 (06): : E339 - E346
  • [9] Effect of Upadacitinib on Reducing Pain in Patients With Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drug
    Atul, Deodhar
    Xenofon, Baraliakos
    Iain, McInnes
    Kurt, de Vlam
    Louis, Bessette
    Anna, Maniccia
    Ralph, Lippe
    Christopher, Saffore
    Gao Tianming
    In-Ho, Song
    Andrew, Ostor
    SWISS MEDICAL WEEKLY, 2021, 151 : S22 - S22
  • [10] SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, MEASURE 2
    Baraliakos, X.
    Schiff, M.
    Pavelka, K.
    Widmer, A.
    Porter, B.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 358 - 358
12345